[1]
Dimachkie , M.M. et al. 2021. Phase II Study of Arimoclomol in IBM FDA-OOPD . RRNMF Neuromuscular Journal. 2, 3 (Aug. 2021), 104–142. DOI:https://doi.org/10.17161/rrnmf.v2i3.15728.